Cumberland Pharmaceuticals (CPIX) EBITDA Margin (2010 - 2026)
Cumberland Pharmaceuticals' (CPIX) quarterly EBITDA Margin came in at 1898.65% in Q2 2026, down 107945.0% year-over-year from N/an in Q2 2025, and down 5440.3% quarter-over-quarter from 34.27% in Q1 2026.
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) EBITDA Margin (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has disclosed EBITDA Margin across 17 years of filings, most recently posting 1898.65% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 107945.0% year-over-year to 1898.65%; the TTM figure through Jun 2026 stood at 30.79% (down 1382.0% YoY), while the FY2025 annual figure was 6.27%, up 1072.0% from the prior year.
- EBITDA Margin came in at 1898.65% for Q2 2026 at Cumberland Pharmaceuticals, down from 34.27% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 11.03% in Q1 2025 to a low of 1898.65% in Q2 2026.
- Average EBITDA Margin over 5 years is 166.75%, with a median of 18.22% recorded in 2022.
- Year-over-year, EBITDA Margin surged 4841 bps in 2024 and tumbled 107945 bps in 2026.
- Over 5 years, EBITDA Margin stood at 24.97% in 2022, then sank by 165 bps to 66.07% in 2023, then jumped by 73 bps to 17.65% in 2024, then jumped by 43 bps to 10.02% in 2025, then tumbled by 18840 bps to 1898.65% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 1898.65% in Q2 2026, 34.27% in Q1 2026, and 10.02% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.38 Bn | 624.62 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 443.13 Bn | 436.56 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 365.40 Bn | 358.26 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 266.79 Bn | 259.10 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 43.92 Bn | 43.92 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 21.55 Bn | 18.88 Bn | 683.80 Mn | 42.23% |
| 10 | Cumberland Pharmaceuticals | 95.51 Mn | 91.65 Mn | - | -1,898.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,898.65% |
| Mar 31, 2026 | -34.27% |
| Dec 31, 2025 | -10.02% |
| Sep 30, 2025 | -23.70% |
| Jun 30, 2025 | -819.21% |
| Mar 31, 2025 | 11.03% |
| Dec 31, 2024 | -17.65% |
| Sep 30, 2024 | -18.65% |
| Jun 30, 2024 | -10.42% |
| Mar 31, 2024 | -22.00% |
| Dec 31, 2023 | -66.07% |
| Sep 30, 2023 | -18.51% |
| Jun 30, 2023 | 0.21% |
| Mar 31, 2023 | -16.60% |
| Dec 31, 2022 | -24.97% |
| Sep 30, 2022 | -2.53% |
| Jun 30, 2022 | -17.93% |
| Mar 31, 2022 | -11.56% |
| Dec 31, 2021 | -52.33% |
| Sep 30, 2021 | -19.37% |